UPDATE: Morgan Stanley Initiates AbbVie at Equal-Weight; Heavy Reliance on Humira
Posted on January 03, 2013 at 13:42 PM EST
Morgan Stanley initiated coverage on AbbVie (NYSE: ABBV ) with an Equal-weight rating and a $36 price target. Morgan Stanley noted, "AbbVie (ABBV) biopharma separated from Abbott. We are EW given heavy reliance on Humira and 6% EV/EBITDA premium to global median, offset by attractive yield. Our $36 PT